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Reveˆtements fonctionnels, UPRES EA 1040, ENSCL, Villeneuve d’Ascq, FrancePurpose. Cyclodextrins (CDs) are torus shaped cyclic oligosaccharides with a hydrophobic internal cavity and a hydrophilic
external surface. We performed and analysed an antibiotic binding on Dacron (polyethyleneterephtalate, PET) vascular
grafts, previously coated with CDs based polymers.
Methods. The CDs coating process was based on the pad-dry-cure method patented in our laboratory. The Dacron
prostheses were immersed into a solution containing a polycarboxylic acid, a cyclodextrin and a catalyst, and placed into a
thermofixation oven before impregnation with an antibiotic solution (Vancomycin). Biocompatibility tests were performed
with L132 human epithelial cells. The antibiotic release in an aqueous medium was assessed by batch type experiments using
UV spectroscopy.
Results. Viability tests confirmed that the CDs polymers coating the Dacron fibers were not toxic towards L132 cell. Cell
proliferation was similar on coated and uncoated grafts.
A linear release of Vancomycin was observed over 50 days.
Conclusion. Our results demonstrate the feasibility of coating CDs onto vascular Dacron grafts. Biological tests show no
toxicity of the different cyclodextrins coated. A linear release of antibiotics was depicted over 50 days, demonstrating that
cyclodextrin grafting was an efficient drug delivery system.Keywords: Drug delivery system; Polyethyleneterephtalate; Vascular grafts; Graft coating.Various modifications have been applied to Dacron
(polyethyleneterephtalate, PET) and ePTFE grafts to
improve their thrombogenicity and durability. One
option is to develop a drug-delivery-system vascular
graft, with attachment of active (e.g. anticoagulant,
antithrombotic, antibiotics, growth factors) agents to
the graft. Amajor concern is the duration of the agents’
function on the graft surface. Various methods are
described to attach the ‘drug’ to the vascular graft and
progressively release it: including heparin ionic bind-
ing with a cationic agent (tridodecil-methyl-
ammonium-chloride),1 silver ions incorporated to the
collagen sealant coating,2 Rifampicin ionically boundas presented at the XVIII annual meeting of the
ciety for Vascular Surgery, 17–19 September 2004,
ustria.
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0628+ 05 $35.00/0 q 2005 Elsevier Ltd. All rights reserto modified gelatin,3 fibroblast growth factor incor-
porated in fibrin glue impregnated on the vascular
graft,4 plasma polymerization (deposition of polymers
under the influence of partially ionized gas),5 tissue
engineering.6
Cyclodextrins (CDs) are truncated torus shaped
cyclic oligosaccharides, issued from enzymatic degra-
dation of starch. They are made of 6–8 glucopyranosic
units (a, b, and g-CD, respectively), with a hydro-
phobic internal cavity and a hydrophilic external
wall.7–9 This configuration allows the CDs to capture
various active molecules (e.g. biocides, fragrances,
dyes, drugs) and progressively release them unmodi-
fied.10 The coating technique of CDs onto textile
Dacron was developed in our laboratory and pre-
viously reported.11,12 The Dacron fibers are coated by a
polymer network of cross-linked CDs. It has already
been reported that CDs have the ability to interact with
antiseptics and antibiotics, such as Chlorhexidine,Eur J Vasc Endovasc Surg 29, 628–632 (2005)
doi:10.1016/j.ejvs.2005.02.020, available online at http://www.sciencedirect.com onved.
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delivery action.8
We performed and analysed the binding of an
antibiotic onto a Dacron vascular graft, previously
coated with cyclodextrins.Material and Methods
The Dacron graft was a polythese vascular graft
provided by Laboratoires Perouse (Ivry-Le-Temple,
France), with the following characteristics: woven PET,
2 yarns of 100 dTex, 24 mm diameter, crimped, surface
weight Z133 g/m2. b-CDs and g-CD were gifts from
Roquette (Lestrem, France) andWacker Chemie GmbH
(Burhausen, Germany), respectively. Citric acid (CTR)
(used as crosslinking agent) and sodium dihydrogen
hypophosphite (catalyst) were provided by Aldrich
chemicals (Milwaukee, WI, USA).Cyclodextrin grafting
The coating process was based on the pad-dry-cure
method, currently applied in the textile industry.14
CDs, catalyst and CTR were solubilized in water.
Prostheses were impregnated by this solution, roll-
squeezed and dried at 90 8C. Coating was performed
in a thermofixation oven. Polymerisation by polycon-
densation between CTR and CDs occurred during this
step and resulted in a crosslinked CD polymer that
physically adhered to the Dacron fibers. The modified
prostheses were finally rinsed with warm water and
were then submitted to successive extractions with
hexane, ethanol, and water, in order to eliminate
unreacted products. The rate of CDs coated onto the
Dacron grafts was related to the temperature and the
time of the thermofixation reaction. It was evaluated
according to the weight increase of the prostheses.
Prostheses with 5%-wt and 10%-wt were used in the
following experiments.Biological tests
Biological tests were carried out to observe if the
polymerized CDs located on the surface of the graft
modified the Dacron biocompatibility. Human epi-
thelial embryonic cells (cell-line L132, ATCC-CCL5)
were used for all biological tests. Cells were incubated
at 37 8C in a 5% CO2 atmosphere with a 100% relative
humidity. Earl’s minimum essential medium (MEM)
supplemented with 5% foetal calf serum containing
L-glutamine (Gribco BRL), streptomycin (0.1 g/l) and
penicillin (100 UI/ml) was used. To assess cellproliferation, a disk of each textile sample (untreated
Dacron, 5% wt-CDs and 10% wt-CDs coated Dacron,
and Nickel) was placed in the bottom of a 15.5 mm
Multiwell plate (COSTAR 24 wells) with sterile
forceps.15 For each sample, four replicates were
performed. On each disk, 10,000 cells in 1 ml of culture
medium supplemented with 5% foetal calf serum
(Eurobio) were placed. Cell proliferation in empty
culture chambers was also assessed (control group).
The culture chambers were separately harvested with
trypsin 3 and 6 days after the beginning of the
experiment. Cell counting was performed (three
times for each sample) using a Coulter ZI cell counter.
Cell proliferation rate was calculated as a ratio
between the number of cells on the textile and the
number of cells in the empty control culture chambers.
Viability tests assessed the relative plating efficiency
(RPE) and subsequently, the 50% lethal concentration
(LC50), using the colony forming method on culture of
human epithelial cells (L132).15 Cells were incubated
for 9 days in MEM medium supplemented with 10%
foetal bovine serum under 5% CO2 atmosphere. Cells
were continuously exposed to increasing concen-
trations (0, 25, 50, 100, 200, and 400 mg/ml) of polymer
of CDs, untreated Dacron (negative control), and
Nickel (positive control), without renewal of the
growth medium during the experiments. Eight similar
experiments were performed for each concentration.
After the incubation period, the medium was with-
drawn and the colonies were coloured with crystal
violet dye. After drying, the clones were counted with
a binocular microscope.Antibiotic binding and release quantification
gCDs-coated (5 and 10%-wt grafting rates) grafts were
immersed into a 5 g/l solution of Vancomycin (Van-
comycin chlorydrate, Merck, Darmstadt, Germany) for
4 h. For each sample, four replicates were performed.
They were dried for 12 h at 37 8C. The samples were
placed in physiologic medium for 80 days. Every day,
an aliquot of physiologic medium was withdrawn and
analysed by UV spectroscopy (Fluorocount—Pakard)
at 280 nm to quantify the amount of Vancomycin
released by the CD-coated graft.ResultsBiological tests
Viability tests (Fig. 1) revealed no toxicity of b-CD and
g-CD polymer. A minimum of 50% survival rate wasEur J Vasc Endovasc Surg Vol 29, June 2005
N. Blanchemain et al.630always observed. CD-coated samples showed similar
viability tests results compared to uncoated Dacron.
Proliferation tests (Fig. 2) confirmed these results. L132
cells did not proliferate on woven Dacron (12%
proliferation after 3 days, decreasing at 3% after 6
days). On CD-coated Dacron samples, the results were
similar (19% proliferation after 3 days decreasing at
5% after 6 days).Antibiotic release
The release of Vancomycin (Fig. 3) was linear during
more than 50 days at a rate of 0.30 mg/l/day and
0.13 mg/l/day, respectively, for 10%-wt and 5%-wt
coated g-CD prostheses. Untreated Dacron grafts
released the total amount of antibiotic within 1 h into
the batch aqueous medium.Discussion
This study demonstrated the feasibility of cyclodextrin
coating on vascular Dacron grafts using a process
previously developed12 by our laboratory. It also
demonstrated that the Dacron–cyclodextrin associ-
ation was an efficient drug delivery system. The
degree of polymerization and the crosslinking rate of
the CD-polymer fashioned in the Dacron fiber network
allowed formation of a stable three dimensional CD-
polymer network. A different process is currently
being developed to coat expended PTFE with CDs.
We, therefore, focused our investigations on theFig. 1. Viability of human embryonic epithelial cells L132
after a 9-day exposure to increasing concentrations of beta-
cyclodextrin, gamma-cyclodextrin, Nickel and pure
untreated PET (LC50Z50% lethal concentration).
Eur J Vasc Endovasc Surg Vol 29, June 2005development of a drug delivery system on Dacron
prostheses. Some authors report that ePTFE, with its
microporous structure, offers a better resistance to
graft infection compared to Dacron.16 However, most
clinical series report no significant difference in
infection rate when comparing Dacron and ePTFE
vascular grafts.17
CDs are considered ‘high performance pharmaceu-
tical excipients’.18 Their toxicity has been evaluated,
depending on the route of administration, the cavity
size (a, b or g-CD), and chemical modification
(hydroxypropyl-CD, sulfobutylether-CD, CD sul-
phate, methylated CD). Therefore, it was important
in the present project to verify the innocuous nature of
the polymerized CD present on the surface of the
modified Dacron fibers. The biological tests we
performed did not demonstrate any toxicity of the
CD-polymers on the Dacron surface. Cell proliferation
tests showed a low proliferation and activity of human
embryonic epithelial cells L132. CD-coating did not
modify cell response compared to untreated Dacron.
The external component of the cyclodextrins, which
contains many hydrophilic hydroxide groups, could
improve the interaction between the PET and the cells.
Infection of vascular grafts occurs in 1–5% of
patients. Most early (!4 months) and late infections
are secondary to graft contamination during the initial
procedure. Late infections can also be secondary to
bowel fistula, redo procedures and false aneurysms.
The site of the arterial reconstruction has a major
incidence on the rate of infection and the bacteria
involved. Graft infection treatment is associated with a
high rate of morbidity and mortality, with significant
time and cost implications. It was previously demon-
strated in an experimental animal study that systemic
antibiotic prophylaxis associated with local antibiotic
prophylaxis significantly decreases the incidence of
graft infection.19 We, therefore, focused the develop-
ment of our vascular graft drug delivery system
towards antibiotic release. Vancomycin, the antibiotic
used in the present study, was selected because of its
stability in physiological medium. The release of
antibiotic was, therefore, easily quantified by UV
spectroscopy. A linear release of Vancomycin in
physiological medium was depicted over a 50-day
period. Our study aim was to demonstrate the
feasibility of CD grafting and the linear in vitro release
of an antibiotic. We do not recommend the use of
Vancomycin for the treatment of primary or secondary
grafts infections. Experimental and clinical data with
Rifampicin-bounded Dacron grafts have reported
inhibition of bacterial growth and reduction in graft
infection rate.20–23 Rifampicin binding on Dacron
grafts previously coated with cyclodextrin could be
Fig. 2. Proliferation of human embryonic epithelial cells L132 (at 3 and 6 days) onNickel, untreated PET, and beta and gamma
CD coated Dacron.
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early graft infection. The release of Rifampicin by CDs-
Dacron grafts is currently under investigation in our
laboratory. Other antibiotics, depending on the type ofFig. 3. Release of Vancomycin in physiologic medium during 80
Dacron prosthesis (coating rate of 5 and 10%).infection, could also be bound to CDs-Dacron grafts in
the setting of late infection.
This study confirmed that cyclodextrins coating
was an efficient drug delivery system adapted todays. Results with uncoated and gamma cyclodextrin coated
Eur J Vasc Endovasc Surg Vol 29, June 2005
N. Blanchemain et al.632antibiotics. Many other active molecules could be
attached on the vascular prostheses: antithrombotic
agents, cell growth or inhibitor factors, extra-cellular
matrix. Their evaluation is also scheduled in the
present research program.Acknowledgements
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